These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 11980672

  • 1. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
    Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT.
    Cancer Res; 2002 May 01; 62(9):2708-14. PubMed ID: 11980672
    [Abstract] [Full Text] [Related]

  • 2. Correspondence Re S. S. Virtanen et al., Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-14. Re K. Sawada et al., Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2002;62:6015-20.
    Andela VB.
    Cancer Res; 2004 Apr 15; 64(8):2934-5; author reply 2935-6. PubMed ID: 15087415
    [No Abstract] [Full Text] [Related]

  • 3. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW.
    J Urol; 2003 Jul 15; 170(1):246-52. PubMed ID: 12796698
    [Abstract] [Full Text] [Related]

  • 4. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
    Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA.
    Proc Natl Acad Sci U S A; 1999 Jan 05; 96(1):133-8. PubMed ID: 9874784
    [Abstract] [Full Text] [Related]

  • 5. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho.
    Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, Murata Y.
    Cancer Res; 2002 Nov 01; 62(21):6015-20. PubMed ID: 12414621
    [Abstract] [Full Text] [Related]

  • 6. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
    Iguchi K, Tatsuda Y, Usui S, Hirano K.
    Eur J Pharmacol; 2010 Sep 01; 641(1):35-40. PubMed ID: 20519142
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS.
    Eur J Pharmacol; 2007 Sep 10; 570(1-3):27-37. PubMed ID: 17640631
    [Abstract] [Full Text] [Related]

  • 8. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G.
    Arch Biochem Biophys; 2000 Jan 01; 373(1):231-41. PubMed ID: 10620343
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
    Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H.
    Cancer Res; 2001 Jun 15; 61(12):4885-91. PubMed ID: 11406567
    [Abstract] [Full Text] [Related]

  • 10. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul 15; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul 15; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR.
    Bone; 2006 Feb 15; 38(2):154-66. PubMed ID: 16126463
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of tumor formation by snake venom disintegrin.
    Yang RS, Tang CH, Chuang WJ, Huang TH, Peng HC, Huang TF, Fu WM.
    Toxicon; 2005 Apr 15; 45(5):661-9. PubMed ID: 15777962
    [Abstract] [Full Text] [Related]

  • 14. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, Séronie-Vivien S.
    BMC Cancer; 2006 Mar 15; 6():60. PubMed ID: 16539721
    [Abstract] [Full Text] [Related]

  • 15. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E, Löwik C, van der Pluijm G, Papapoulos S.
    J Bone Miner Res; 1999 May 15; 14(5):722-9. PubMed ID: 10320520
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
    Kusama T, Mukai M, Tatsuta M, Nakamura H, Inoue M.
    Int J Oncol; 2006 Jul 15; 29(1):217-23. PubMed ID: 16773203
    [Abstract] [Full Text] [Related]

  • 17. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro.
    Muller S, Migianu E, Lecouvey M, Kraemer M, Oudar O.
    Anticancer Res; 2005 Jul 15; 25(4):2655-60. PubMed ID: 16080508
    [Abstract] [Full Text] [Related]

  • 18. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFalpha, macrophages, and T-cells.
    Deng X, Yu Z, Funayama H, Yamaguchi K, Sasano T, Sugawara S, Endo Y.
    Int Immunopharmacol; 2007 Feb 15; 7(2):152-61. PubMed ID: 17178381
    [Abstract] [Full Text] [Related]

  • 19. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines.
    Cheng YY, Huang L, Lee KM, Li K, Kumta SM.
    Pediatr Blood Cancer; 2004 May 15; 42(5):410-5. PubMed ID: 15049011
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
    Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P.
    Cancer Res; 2000 Jun 01; 60(11):2949-54. PubMed ID: 10850442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.